Date: October 1, 2026

KMP / Board / Auditor Changes

Re-appointments

  • Mr. Nikhil P. Desai (DIN: 01660649) re-appointed as CEO & Managing Director for a consecutive term of 5 years, effective from August 20, 2027 to August 19, 2032. He shall not be liable to retire by rotation.
  • Mr. Santosh M. Kakade (DIN: 08505234) re-appointed as Whole-time Director designated as Executive Director for a consecutive term of 5 years, effective from August 20, 2027 to August 19, 2032. He shall be liable to retire by rotation.

New Appointment

  • Prof. Vandana B. Patravale (DIN: 09200693) appointed as Independent Director for a term of 5 years, effective from August 22, 2026 to August 21, 2031.

Director Profiles and Relationships

  • Mr. Nikhil P. Desai: Has over 20 years of experience across Information Technology, Project Management, Technical Sales, Vendor Management, Team Building, Process Improvement, Business Strategy, Change Management, Marketing and Product Development. Has significant exposure to pharmaceutical and chemical industries. He is the son of Mr. Parimal H. Desai, Non-Executive Director and Promoter of the Company, and forms part of the Promoter Group.
  • Mr. Santosh M. Kakade: Has more than three decades of diverse experience in Plant Operations, Process Development, Project Management, and General Management. Not related to any Director of the Company.
  • Prof. Vandana B. Patravale: Holds B. Pharm., M. Pharm. and Ph.D. (in Pharmaceutics) from University of Mumbai. Senior Professor of Pharmaceutics at Institute of Chemical Technology (ICT), Mumbai with over 35 years of academic, research and industry-oriented experience. Expertise includes Pharmaceutics, Cosmeticology, Validation and Regulatory Affairs, and Advanced Pharmaceutics. Has supervised numerous research projects and contributed to development of novel nanocarriers for cosmeceuticals and applications in malaria, cancer and neurodegenerative disorders. Has extensive research publications and intellectual property including several Indian and International patents. Recipient of Abdul Kalam National Innovation Fellowship, OPPI Woman Scientist Award, VASVIK Industrial Research Award and UAA-ICT Distinguished Alumnus Award. Played significant role in successful transfer of several Pharmaceutical Technologies. Not related to any Director of the Company.

Compliance Status

All three individuals are not debarred from holding the office of Director pursuant to any order of SEBI or any other authority.

Approval Authority

All changes were approved by Members of the Company at the 8th Annual General Meeting held on Tuesday, September 29, 2026, based on the report of the Scrutinizer dated September 30, 2026.

Regulatory Basis

Disclosure made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular dated January 30, 2026.